PIK3C3 and neoplasm: The increased anti‐tumor efficacy of ADU‐S100 in combination treatment with VPS34i in vivo further suggests that pharmacological VPS34 inhibition may be a promising strategy to increase immune cell infiltration and improve responses to existing and emerging cancer immunotherapies.